A brilliant scientist, Oppenheimer was tasked with the development of the atomic bomb in the top-secret Manhattan Project at Los Alamos, New Mexico during World War II.

Oppenheimer analysts downgraded Pliant Therapeutics stock from Outperform to Perform, following a significant development ...

(JTA) — Friday is not just “Barbie” release day — moviegoers are also planning to fill theaters across the United States to see Christopher Nolan’s “Oppenheimer” biopic. Many hope it ...

This information was highlighted following a recent meeting between Oppenheimer analysts and Veru's management in San Francisco, which increased their confidence in the trial's success.

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for ...

Oppenheimer analyst Jeff Jones downgraded Pliant Therapeutics (PLRX) to Perform from Outperform without a price target after the company ...

About Chemomab Therapeutics Ltd. Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of ...

Annovis Bio's CEO to present at Oppenheimer's conference, discussing Phase 3 trial progress and NDA initiatives for buntanetap. Annovis Bio Inc. has announced that its CEO, Dr. Maria Maccecchini ...

Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering ...

This information was highlighted following a recent meeting between Oppenheimer analysts and Veru's management in San Francisco, which increased their confidence in the trial's success. The QUALITY ...